{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:13:06Z","timestamp":1767924786070,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,11,20]],"date-time":"2012-11-20T00:00:00Z","timestamp":1353369600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s10637-012-9895-6","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T08:38:39Z","timestamp":1353314319000},"page":"910-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Takayuki","family":"Yoshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomu","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Asayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahiro","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,20]]},"reference":[{"key":"9895_CR1","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/70928","volume":"5","author":"N Ferrara","year":"1999","unstructured":"Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359\u20131364","journal-title":"Nat Med"},{"key":"9895_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27\u201331","journal-title":"Nat Med"},{"key":"9895_CR3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182\u20131186","journal-title":"N Engl J Med"},{"key":"9895_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1084\/jem.136.2.261","volume":"136","author":"MA Gimbrone Jr","year":"1972","unstructured":"Gimbrone MA Jr, Leapman SB, Cotran RS et al (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261\u2013276","journal-title":"J Exp Med"},{"key":"9895_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","volume":"29","author":"J Folkman","year":"2002","unstructured":"Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15\u201318","journal-title":"Semin Oncol"},{"key":"9895_CR6","first-page":"1459","volume":"62","author":"HF Dvorak","year":"1979","unstructured":"Dvorak HF, Dvorak AM, Manseau EJ, Wiberg L, Churchill WH (1979) Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst 62:1459\u20131472","journal-title":"J Natl Cancer Inst"},{"key":"9895_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/jnci\/87.3.213","volume":"87","author":"HT Zhang","year":"1995","unstructured":"Zhang HT, Craft P, Scott PA et al (1995) Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87:213\u2013219","journal-title":"J Natl Cancer Inst"},{"key":"9895_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF00437469","volume":"15","author":"KP Claffey","year":"1996","unstructured":"Claffey KP, Robinson GS (1996) Regulation of VEGF\/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 15:165\u2013176","journal-title":"Cancer Metastasis Rev"},{"key":"9895_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391\u2013400","journal-title":"Nat Rev Drug Discov"},{"key":"9895_CR10","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393\u201311398","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9895_CR11","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593\u20134599","journal-title":"Cancer Res"},{"key":"9895_CR12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nrc2524","volume":"8","author":"C Fischer","year":"2008","unstructured":"Fischer C, Mazzone M, Jonckx B, Carmeliet P (2008) FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8:942\u2013956","journal-title":"Nat Rev Cancer"},{"key":"9895_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","volume":"131","author":"C Fischer","year":"2007","unstructured":"Fischer C, Jonckx B, Mazzone M et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463\u2013475","journal-title":"Cell"},{"key":"9895_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","volume":"52","author":"A Jemal","year":"2002","unstructured":"Jemal A, Thomas A, Murray T et al (2002) Colorectal cancer incidence, mortality and survival in South-east England between 1972 and 2001: Cancer statistics. CA Cancer J Clin 52:23\u201347","journal-title":"CA Cancer J Clin"},{"key":"9895_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics. CA Cancer J Clin 55:74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"9895_CR16","first-page":"35","volume":"46","author":"H Saito","year":"2000","unstructured":"Saito H (2000) Colorectal cancer screening in Japan. Jpn J Cancer Clin 46:35\u201342","journal-title":"Jpn J Cancer Clin"},{"key":"9895_CR17","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499\u20133506","journal-title":"J Clin Oncol"},{"key":"9895_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9895_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38:29\u201341","journal-title":"Biometrics"},{"key":"9895_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1200\/JCO.2009.22.9237","volume":"28","author":"AC Lockhart","year":"2010","unstructured":"Lockhart AC, Rothenberg ML, Dupont J et al (2010) Phase I study of intravenous vascular endothelial growth factor Trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28:207\u2013214","journal-title":"J Clin Oncol"},{"key":"9895_CR21","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Khayat D, Verslype C et al (2012) Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer [Epub ahead of print]","DOI":"10.1016\/j.ejca.2012.07.007"},{"key":"9895_CR22","doi-asserted-by":"publisher","first-page":"18363","DOI":"10.1073\/pnas.0708865104","volume":"4","author":"JS Rudge","year":"2007","unstructured":"Rudge JS, Holash I, Hylton D, Russell M, Jiang S, Leidich R (2007) VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 4:18363\u201318370","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9895_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229\u2013237","journal-title":"J Clin Oncol"},{"key":"9895_CR24","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853\u2013860","journal-title":"Lancet Oncol"},{"key":"9895_CR25","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706\u20134713","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9895-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10637-012-9895-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9895-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9895-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:34:19Z","timestamp":1678509259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-012-9895-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,20]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["9895"],"URL":"https:\/\/doi.org\/10.1007\/s10637-012-9895-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,20]]},"assertion":[{"value":"9 August 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}